AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Antibody Demonstrates Novel Immune Mechanism.(OvaRex monoclonal antibody from AltaRex Corp.)
2001 AUG 15 - (NewsRx.com & NewsRx.net) --
AltaRex Corp. (ALXFF.OTC) presented evidence that, in response to the patient's circulating CA125 antigen, its OvaRex(R) monoclonal antibody (MAb) helps produce an immune response in ovarian cancer patients by which patient-generated antibodies become directed against various sites on the CA125 antigen.
These results were published in a recent issue of the journal Cancer Biotherapy and Radiopharmaceuticals. The data were derived in part from an analysis of 100 OvaRex-treated ovarian cancer patients in Germany. Early in the development program for OvaRex MAb, investigators attributed observed clinical benefit to the network theory of antibody induction, or the idiotypic network. The published data demonstrate that the classical idiotype network is operative, but is not the dominant mechanism of OvaRex MAb.
The paper presented considerable evidence for antibody (OvaRex)-mediated antigen processing and presentation of tumor-associated antigen (CA125) with immune recognition that results in multi-epitopic antigen (CA125)-specific B- and T-cell responses. Notably, AltaRex was recently (June 2001) issued a U.S. patent for the method of treatment with OvaRex MAb that elicits this predominant multi-epitopic response mechanism.
As discussed in the paper, analysis of patient samples from pharmacokinetic studies demonstrated that OvaRex MAb forms immune complexes in circulation with the ovarian-cancer-associated antigen CA125 within 30 minutes of a 2 mg injection of the antibody. In ...
- OvaRex MAb for Patients with Advanced Ovarian Cancer May Extend Remission...
- Press release article from: Business Wire February 10, 2005 700+ words
...Results of the most recently completed OvaRex MAb clinical study were published in the...treatment" group, patients who received OvaRex MAb experienced a longer period of remission...treatment. "We've learned so much about OvaRex MAb but we now need to confirm these observations...
- ViRexx announces enrolment completion of Ovarex MAb Phase III trial for ovarian...
- News wire article from: Chemical Business Newsbase December 14, 2005 700+ words
...of two identical Phase III trials for OvaRex MAb, Impact I and Impact II. The Impact...completed front-line therapy. The OvaRex MAb trials are being conducted and funded...trial is 177 patients, randomised 2:1 OvaRex MAb versus placebo. The primary endpoint...
- ViRexx announces completion of enrollment for Phase III OvaRex MAb trials.
- News wire article from: Chemical Business Newsbase June 22, 2006 700+ words
...s (Unither), Phase III trials for OvaRex MAb for patients with stage III/IV advanced...trial is time-to-relapse comparing OvaRex MAb and placebo with the primary data analysis...controlled trials, randomised 2:1 OvaRex MAb versus placebo, are being conducted...
- PRESS RELEASE: AltaRex to present OvaRex MAb in Europe at ECCO 11 meeting.
- News wire article from: Chemical Business Newsbase October 31, 2001 700+ words
AltaRex Corp announced that OvaRex MAb, the company's lead product in late...and the patient's own tumour) when OvaRex MAb was administered after surgery and then...findings from this study demonstrate that OvaRex MAb did not diminish the effect of salvage...
- Press Release: AltaRex achieves major manufacturing milestone for OvaRex Mab.
- News wire article from: Chemical Business Newsbase January 9, 2002 700+ words
...to file an amendment to its Investigational New Drug submission for OvaRex MAb with the US Food and Drug Administration (FDA) and to commence the...company's Biologics License Application for regulatory approval of OvaRex MAb.
- Dompe International SA, of Lausanne, Switzerland, and AltaRex Medical Corp., of...
- Newspaper article from: BioWorld International July 14, 2004 700+ words
...and AltaRex Medical Corp., of Edmonton, Alberta, signed an exclusive distribution agreement for AltaRex's lead product OvaRex MAb. The covered territory includes Italy, Spain, Portugal, Hungary, Poland, Czech Republic, Switzerland and Austria...
- OvaRex MAb Selected as one of 100 Great Investigational Drugs.
- Press release article from: Business Wire May 18, 2004 700+ words
Business Editors EDMONTON, AlbertaBUSINESS WIREMay 18, 2004 AltaRex Medical Corp. (TSX: ALT) ("AltaRex" or the "Company") is pleased to announce that the Company's lead product candidate, OvaRex(R) MAb, has been selected by R&D Directions magazine as one of 100 Great Investigational Drugs. The
- ViRexx announces completion of enrollment for Phase III OvaRex'R' MAb trials.
- News wire article from: Chemical Business Newsbase June 23, 2006 700+ words
...s (Unither), Phase III trials for OvaRex MAb for patients with stage III/IV advanced...available in the mid portion of 2007. The OvaRex MAb trials are being conducted and funded...trial is time-to-relapse comparing OvaRex MAb and placebo with the primary data analysis...
- ViRexx announces comprehensive partnership for OvaRex'R' Mab.
- News wire article from: Chemical Business Newsbase November 6, 2006 700+ words
...manufacturing, licensing and distribution of OvaRex MAb to its remaining unlicensed European...Tecnogen will manufacture and supply OvaRex MAb for all of ViRexx's European licensing...25% to ViRexx Ireland on net sales of OvaRex MAb in the European and Middle Eastern countries...
- ViRexx provides affirmation of clinical progress and anticipated milestones;...
- News wire article from: Asia Africa Intelligence Wire June 9, 2005 700+ words
...products, including a Phase III product, OvaRex MAb, a therapy for the treatment of late...4Q 2005; completion of enrolment in OvaRex MAb Phase III trial early in 2006. ViRexx...of a late-stage clinical product, OvaRex MAb, and oncology platform through acquisition...
Source: HighBeam Research, Antibody Demonstrates Novel Immune Mechanism.(OvaRex monoclonal...